Shareholding disclosure

NGN Capital LLC

Declared position

3.27%

Threshold

Crossed upwards

Timeline

Published

07.05.2013

Transaction

09.04.2013

Voting rights breakdown

Voting rights acquired3.27%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAD5300018

Beneficial owner

NGN Capital LLC

Declared address

NGN Capital LLC, New York, NY 10017

Our Funds, NGN BioMed Opportunity I, LP and NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG are shareholders in Santhera Pharmaceuticals Holding AG.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

NGN Capital LLC

Santhera Pharmaceuticals Holding AG07.05.2013TAD5300018

Disclosure summary

NGN Capital LLC disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 07.05.2013, at 3.27% of voting rights. Notice category: Single shareholder.

Disclosed position

3.27%

Voting rights acquired

Voting rights acquired3.27%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

NGN Capital LLC disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 07.05.2013.

Publication date07.05.2013

Transaction date09.04.2013

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerNGN Capital LLC

Declared addressNGN Capital LLC, New York, NY 10017

CategorySingle shareholder

Voting rights acquired3.27%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAD5300018

Conditions

Our Funds, NGN BioMed Opportunity I, LP and NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG are shareholders in Santhera Pharmaceuticals Holding AG.

Source: SIX Exchange Regulation · Publication date: 07.05.2013

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open